Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A More COMPLETE Picture of Revascularization in STEMI

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Ticagrelor in Patients with Stable Coronary Disease and Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM

    Research output: Contribution to journalReviewResearchpeer-review

  2. Reply to: Clinical impact of high platelet count and high hematocrit, by Marc Sorigue

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Obesity as a Causal Risk Factor for Aortic Valve Stenosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Incidental lymphopenia and mortality: a prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • AKCEA-APO(a)-LRx Study Investigators
View graph of relations

BACKGROUND: Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower lipoprotein(a) levels.

METHODS: We conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter). Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-LRx, referred to here as APO(a)-LRx (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months. The lipoprotein(a) level was measured with an isoform-independent assay. The primary end point was the percent change in lipoprotein(a) level from baseline to month 6 of exposure (week 25 in the groups that received monthly doses and week 27 in the groups that received more frequent doses).

RESULTS: The median baseline lipoprotein(a) levels in the six groups ranged from 204.5 to 246.6 nmol per liter. Administration of APO(a)-LRx resulted in dose-dependent decreases in lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.003 to <0.001). There were no significant differences between any APO(a)-LRx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms. The most common adverse events were injection-site reactions.

CONCLUSIONS: APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number, NCT03070782.).

Original languageEnglish
JournalThe New England journal of medicine
Volume382
Issue number3
Pages (from-to)244-255
Number of pages12
ISSN0028-4793
DOIs
Publication statusPublished - 16 Jan 2020

    Research areas

  • Adult, Aged, Cardiovascular Diseases/blood, Cholesterol/blood, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Hypolipidemic Agents/administration & dosage, Least-Squares Analysis, Lipoprotein(a)/blood, Male, Middle Aged, Oligonucleotides/administration & dosage, Risk Factors

ID: 59310635